docetaxel anhydrous has been researched along with Angiogenesis, Pathologic in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.18) | 18.2507 |
| 2000's | 30 (35.29) | 29.6817 |
| 2010's | 50 (58.82) | 24.3611 |
| 2020's | 4 (4.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Bastian, A; Choudhary, S; Gangjee, A; Hamel, E; Ihnat, MA; Pavana, RK | 1 |
| Aguera, KN; Davis, GE; Griffin, CT; Kemp, SS; Koller, GM; Lin, PK; Salvador, J; Xie, J | 1 |
| Ahmad, FJ; Ahmad, I; Akhter, S; Alam Rizvi, MM; Hafeez, Z; Jain, GK; Zafar, S | 1 |
| Alonso-González, C; Cos, S; González, A; González-González, A; Martínez-Campa, C; Menéndez, JM; Mitola, S; Rueda, N | 1 |
| Frank, PG; Goupille, C; Mahéo, K; Vibet, S | 1 |
| Che, K; Li, M; Li, R; Liu, Z; Wang, L; Xiang, S; Yu, Y | 1 |
| Hsu, CW; Huang, R; Li, S; Sakamuru, S; Xia, M; Zou, C | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Hsiao, PW; Hsiao, YW; Hsieh, SC; Tsai, CH; Tsai, MH; Tzeng, SF; Yang, YC | 1 |
| Chen, J; Huan, Y; Huang, M; Jia, Q; Ming, Y; Wang, B; Wang, J; Wang, L; Wang, T; Yao, Q; Zhang, J; Zhou, X | 1 |
| Cai, SQ; Qiang, JW; Qiao, TK; Yuan, SJ | 1 |
| Cai, Y; Feng, J; Gu, J; Huang, J; Liu, H; Qin, J; Qin, Y; Wu, X; Xu, L; Zhu, H | 1 |
| Agarwal, A; Aljumaily, R; Covic, L; Kaimal, R; Kim, YB; Kuliopulos, A; Pradhan, RV; Sharifi, S; Tressel, SL; Zarwan, C | 1 |
| Gao, F; Luo, J; Sun, X; Sun, Z; Wang, H; Zhang, Y; Zhao, X; Zhong, B | 1 |
| Buchholz, S; Engel, JB; Hohla, F; Ortmann, O; Rick, FG; Schally, AV; Seitz, S; Szalontay, L; Treszl, A; Zarandi, M | 1 |
| Belbaraka, R; Elomrani, A; Ismaili, N; Khouchani, M; Tahri, A | 1 |
| Huang, X; Li, S; Wang, L; Wang, X; Yang, Z; Zhang, L; Zheng, X | 1 |
| Chen, HZ; Fang, C; Gao, YG; Guan, YY; Liu, HJ; Liu, YR; Lu, Q; Luan, X; Wang, C; Xu, JR | 1 |
| Ban, X; Cai, Z; Cao, TT; Chen, J; Fu, L; Guan, XY; Huang, P; Li, JB; Li, Y; Qian, C; Qin, Y; Xie, D; Zeng, TT; Zeng, ZL; Zhou, J | 1 |
| Dhakal, I; Griffin, RJ; Hutchins, LF; Jamshidi-Parsian, A; Kadlubar, S; Klimberg, S; Lee, J; Makhoul, I; Raj, V; Siegel, E | 1 |
| Allen, JS; Caruthers, SD; Cui, G; Killgore, K; Kim, B; Lanza, GM; Pan, D; Schmieder, AH; Senpan, A; Shen, B; Wang, K; Wickline, SA; Yang, X; Zhang, H | 1 |
| Chan, MS; Chen, SF; Chow, LW; Felizola, SJ; Ishida, T; Nemoto, N; Ohuchi, N; Sasano, H; Tamaki, K; Wang, L | 1 |
| Deng, WY; Li, N; Li, X; Luo, SX; Song, T | 1 |
| Heigener, D; Reck, M; Reinmuth, N | 1 |
| Alexopoulou, Z; Aravantinos, G; Bafaloukos, D; Bobos, M; Chrisafi, S; Efstratiou, I; Fountzilas, G; Kosmidis, P; Kotoula, V; Kourea, HP; Koutras, A; Papakostas, P; Papaspirou, I; Pectasides, D; Scopa, CD; Skarlos, DV; Varthalitis, I; Zagouri, F | 1 |
| Adams, DJ; Barui, AK; Kulhari, H; Naidu Vegi, GM; Patra, CR; Pooja, D; Shrivastava, S; Sistla, R; Telukutala, SR | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Bronte, G; Galvano, A; Passiglia, F; Russo, A | 1 |
| Chen, Z; Jia, X; Wang, L; Wang, M; Wang, S; Wang, Z; Wu, M; Xu, Z; Zhang, J | 1 |
| Bellmunt, J; Sonpavde, G | 1 |
| Belotte, J; Diamond, MP; Fletcher, NM; Memaj, I; Nusrat, O; Saed, GM; Saed, MG | 1 |
| Cheon, GJ; Chung, JK; Kang, KW; Kim, EE; Kim, YI; Lee, DS; Moon, WK; Paeng, JC; Yoon, HJ | 1 |
| Chow, MS; Hao, J; Huang, Y; Lam, CW; Lau, B; Liu, M; Ravula, R; Shi, L; Song, Y; Wang, J; Wang, Z; Yeung, S | 1 |
| Fang, S; Han, X; Tang, N; Wang, Z; Zhang, Q | 1 |
| Batista de Carvalho, AL; Costa, FM; Diniz, C; Marques, MP; Medeiros, PS; Ribeiro, VP; Sousa, JB | 1 |
| Agarwal, A; Azabdaftari, G; Covic, L; Kaneider, NC; Kuliopulos, A; Lazarides, K; Sevigny, LM; Sharifi, S | 1 |
| Balbi, C; Barboro, P; Benelli, R; Ferrari, N; Monteghirfo, S | 1 |
| Anderson, AR; Ayati, BP; Ciobanu, M; Claridge, J; Gerlee, P; Graham, JM; Hinow, P; Loveless, M; McCawley, LJ; Quaranta, V; Swanson, KR; Wang, S | 1 |
| Aruga, T; Kuroi, K; Matsumoto, G; Muta, M; Nakashima, E; Sai, Y; Saji, S; Suzuki, E; Toi, M; Yanagawa, T | 1 |
| Dahut, WL; Figg, WD; Kluetz, PG | 1 |
| Braun, M; Büttner, R; Friedrichs, N; Höller, T; Kübler, K; Kuhn, W; Mielich, M; Pölcher, M; Rudlowski, C; Wolfgarten, M | 1 |
| de Wit, R; Doyle, GV; Gratama, JW; Miller, MC; Onstenk, W; Rao, C; Schmitz, PI; Sleijfer, S; Strijbos, MH; Terstappen, LW | 1 |
| Allen, CJ; De Souza, R; Moriyama, EH; Piquette-Miller, M; Wilson, BC; Zahedi, P | 1 |
| Groshen, S; Jadvar, H; Lin, E; Markland, FS; Pinski, J; Swenson, S; Wang, Q; Ye, W | 1 |
| Bottsford-Miller, J; Broaddus, RR; Bruckheimer, E; Coffey, D; Coffman, K; Coleman, RL; Gershenson, DM; Han, LY; Hwang, JY; Kamat, AA; Landen, CN; Lin, YG; Lu, C; Merritt, WM; Nick, AM; Nugent, E; Sood, AK; Spannuth, WA; Stone, RL | 1 |
| Cai, MX; Chen, ZK; Huang, J; Ke, LM; Lin, LW; Wei, HF; Xue, ES; Yang, J; Zhang, XJ | 1 |
| Bicknell, R; Cotton, G; Dyer, H; Harrison, T; Hirst, DG; Hookham, M; James, I; McCallum, L; McCarthy, HO; McClelland, K; McGregor, J; McKeen, H; O'Rourke, M; Roberts, J; Robson, T; Valentine, A; Waugh, DJ; Worthington, J; Yakkundi, A | 1 |
| Petrylak, DP | 1 |
| Harrington, JA; Jones, RJ | 1 |
| Alvarez, RD; Coleman, RL; Goodman, B; Han, HD; Katre, AA; Landen, CN; Lopez-Berestein, G; Nick, AM; Sood, AK; Steg, AD; Stone, RL | 1 |
| Aravantinos, G; Bafaloukos, D; Bournakis, E; Dimopoulos, AM; Fountzilas, G; Fountzilas, H; Kalofonos, HP; Kalogeras, KT; Korantzis, I; Kosmidis, P; Kotoula, V; Koutras, A; Papakostas, P; Papaxoinis, G; Pectasides, D; Skarlos, D; Varthalitis, I | 1 |
| Dong, Z; Imai, A; Krishnamurthy, S; Light, E; Nör, JE; Visioli, F; Wang, S; Worden, F; Zeitlin, BD; Zhang, Z | 1 |
| Bahce, I; de Boer, MP; Eriksson, J; Greuter, HN; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Postmus, PE; Serné, EH; Smit, EF; Van der Veldt, AA; Verheul, HM; Walraven, M; Windhorst, AD | 1 |
| Wu, H; Xiao, Y; Xin, Y; Zhao, J | 1 |
| Ernsting, MJ; Foltz, WD; Li, SD; Tagami, T; Undzys, E | 1 |
| Bleuzen, A; Bougnoux, P; Chevalier, S; Goupille, C; Mahéo, K; Richard, S; Serrière, S; Tranquart, F; Vibet, S | 1 |
| Christodoulou, C; Dionysopoulos, D; Fountzilas, G; Kalogeras, KT; Korantzis, I; Kotoula, V; Koutras, A; Linardou, H; Papakostas, P; Papaxoinis, G; Pectasides, D; Samantas, E; Soupos, N | 1 |
| Chen, J; Huan, Y; Jia, Q; Jiang, W; Wang, L; Wei, M; Xu, J; Zheng, M | 1 |
| Ashton, AW; Hotchkiss, KA; Mahmood, R; Russell, RG; Schwartz, EL; Sparano, JA | 1 |
| Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C | 1 |
| Bissery, MC; Bouquet, C; Galaup, A; Griscelli, F; Li, H; Opolon, D; Opolon, P; Perricaudet, M; Tursz, T | 1 |
| Morris, JC | 1 |
| Fujio, N; Horiuchi, T; Kobayashi, M; Koh, Y; Natsume, T; Nishio, K; Ohe, Y; Saijo, N; Watanabe, J | 1 |
| Herbst, RS; Khuri, FR | 1 |
| McConkey, DJ; Nawrocki, ST; Sweeney-Gotsch, B; Takamori, R | 1 |
| Figg, WD; Ng, SS; Sparreboom, A | 1 |
| Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D | 1 |
| Hara, I; Kamidono, S; Miyake, H; Muramaki, M | 1 |
| Bennett, M; Huang, X; Thorpe, PE | 1 |
| Emmenegger, U; Henkin, J; Kerbel, RS; McKay, LM; Veliceasa, D; Volpert, OV; Yap, R | 1 |
| Armstrong, AJ; Carducci, MA | 1 |
| Figg, WD | 1 |
| de las Pozas, A; Perez-Stable, C; Reiner, T | 1 |
| Bhat-Nakshatri, P; Cheng, L; DeGrado, T; Gokmen-Polar, Y; Hutchins, GD; Jayaprakasan, V; Kelich, S; Miller, KD; Miller, MA; Nakshatri, H; Shanmugam, R; Sledge, GW; Sweeney, CJ; Yip-Schneider, M; Zheng, QH | 1 |
| Bischoff, FZ; Coleman, RL; Gershenson, DM; Han, LY; Heymach, JV; Jaffe, RB; Kamat, AA; Kim, TJ; Landen, CN; Lin, YG; Lu, C; Merritt, WM; Sood, AK; Thaker, PH | 1 |
| Cicin, I; Disci, R; Duranyildiz, D; Selam, M; Soydinc, HO; Tas, F; Topuz, E; Uygun, K; Yasasever, V | 1 |
| Hung, H | 1 |
| Coleman, RL; Gershenson, DM; Han, LY; Jennings, N; Kamat, AA; Kim, TJ; Kundra, V; Landen, CN; Langley, R; Lin, YG; Lu, C; Merritt, WM; Ravoori, M; Sood, AK; Spannuth, WA | 1 |
| Broaddus, R; Coffey, D; Coleman, RL; Gershenson, DM; Han, LY; Kamat, AA; Landen, CN; Lin, YG; Lu, C; Merritt, WM; Nugent, E; Patel, PR; Sood, AK; Spannuth, WA | 1 |
| Bar-Eli, MM; De Geest, K; Fletcher, MS; Han, LY; Jennings, N; Kamat, AA; Landen, CN; Langley, RR; Lin, YG; Lopez-Berestein, G; Lutgendorf, SK; Merritt, WM; Sanguino, A; Sood, AK; Spannuth, WA; Villares, G | 1 |
| Marty, M; Pivot, X | 1 |
| Hunter, NR; Mason, KA; Milas, L; Schimming, R | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Larsson, LI; Lichtenberg, J | 1 |
| Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E | 1 |
10 review(s) available for docetaxel anhydrous and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gene Amplification; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neovascularization, Pathologic; Prognosis; Quinazolines; Receptor, ErbB-2; Taxoids; TOR Serine-Threonine Kinases; Trastuzumab | 2013 |
Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Humans; Indoles; Lung Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Ramucirumab; Taxoids; Vascular Endothelial Growth Factor A | 2015 |
Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Ramucirumab; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2016 |
Angiogenesis inhibitors in the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prednisone; Prostatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2010 |
Current clinical trials in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Docetaxel; Hormones; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neovascularization, Pathologic; Orchiectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids | 2011 |
Mode of action of docetaxel - a basis for combination with novel anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Follow-Up Studies; Humans; Male; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pharmacogenetics; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Novel therapeutic approaches to advanced prostate cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cancer Vaccines; Cell Differentiation; Cell Division; Child, Preschool; Clinical Trials as Topic; Disease Management; Docetaxel; Drug Delivery Systems; Enzyme Inhibitors; Humans; Immunotherapy; Male; Neoplasm Proteins; Neovascularization, Pathologic; Prostatic Neoplasms; Signal Transduction; Taxoids | 2005 |
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A | 2008 |
10 trial(s) available for docetaxel anhydrous and Angiogenesis, Pathologic
| Article | Year |
|---|---|
A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Endostatins; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Positron Emission Tomography Computed Tomography; Prospective Studies; Quality of Life | 2018 |
High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Topics: Angiopoietin-1; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fibroblast Growth Factor 2; Humans; Interleukin-1alpha; Matrix Metalloproteinase 9; Neoadjuvant Therapy; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Prospective Studies; Proto-Oncogene Proteins c-sis; Receptor, ErbB-2; Receptor, TIE-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Clinical observation and therapeutic evaluation of Rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Down-Regulation; Endostatins; Esophageal Neoplasms; Female; Humans; Male; Neovascularization, Pathologic; Radiography; Taxoids; Vascular Endothelial Growth Factor A | 2014 |
Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Prospective Studies; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Germany; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Microvessels; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neovascularization, Pathologic; Ovarian Neoplasms; Proportional Hazards Models; Prospective Studies; Taxoids; Time Factors; Treatment Outcome | 2010 |
Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neovascularization, Pathologic; Nitric Oxide; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Thrombospondin 1; Vascular Endothelial Growth Factor A | 2012 |
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neovascularization, Pathologic; Positron-Emission Tomography; Taxoids; Thyroid Gland; Vascular Endothelial Growth Factor A | 2012 |
Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Docetaxel; Endostatins; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Microvessels; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Radiography; Taxoids | 2013 |
Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prospective Studies; Taxoids; Thrombospondin 1; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome | 2002 |
65 other study(ies) available for docetaxel anhydrous and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microtubules; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2017 |
Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Cells, Cultured; Docetaxel; Endothelial Cells; Endothelium, Vascular; Epothilones; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred C57BL; Morphogenesis; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel | 2021 |
Improved chemotherapeutic efficacy against resistant human breast cancer cells with co-delivery of Docetaxel and Thymoquinone by Chitosan grafted lipid nanocapsules: Formulation optimization, in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chitosan; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Screening Assays, Antitumor; Female; Humans; Lipids; MCF-7 Cells; Nanocapsules; Neovascularization, Pathologic; Rats; Structure-Activity Relationship | 2020 |
Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Drug Synergism; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Insulin-Like Growth Factor I; Jagged-1 Protein; Melatonin; Neoplasms; Neovascularization, Pathologic; Receptor, Fibroblast Growth Factor, Type 3; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D; Vinorelbine | 2020 |
EPA and DHA Fatty Acids Induce a Remodeling of Tumor Vasculature and Potentiate Docetaxel Activity.
Topics: Animals; Diet; Docetaxel; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Omega-3; Female; Mammary Neoplasms, Animal; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley | 2020 |
Enhanced antitumor effect on intrapulmonary tumors of docetaxel lung-targeted liposomes in a rabbit model of VX2 orthotopic lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Compounding; Female; Humans; Injections, Intravenous; Liposomes; Lung Neoplasms; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Rabbits; Survival Analysis; Tumor Burden | 2017 |
Identification of Angiogenesis Inhibitors Using a Co-culture Cell Model in a High-Content and High-Throughput Screening Platform.
Topics: Angiogenesis Inhibitors; Bortezomib; Cell Line, Transformed; Coculture Techniques; Docetaxel; Drug Evaluation, Preclinical; Endothelium, Vascular; High-Throughput Screening Assays; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mesenchymal Stem Cells; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Telomerase; Topotecan | 2018 |
A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Macrophages; Male; Mice; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Plant Extracts; Prostatic Neoplasms; Wedelia; Xenograft Model Antitumor Assays | 2017 |
Dynamic contrast enhanced‑magnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer.
Topics: Animals; Carcinoma, Ovarian Epithelial; Contrast Media; Disease Models, Animal; Docetaxel; Female; Humans; Magnetic Resonance Imaging; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley | 2019 |
Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Endothelium, Vascular; Ki-67 Antigen; Lung Neoplasms; Male; Mice; Mice, Nude; Microvessels; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Sirolimus; Specific Pathogen-Free Organisms; Taxoids; Thrombosis; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Docetaxel; Female; Human Umbilical Vein Endothelial Cells; Humans; Matrix Metalloproteinase 14; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Taxoids; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Ulinastatin exerts synergistic effects with taxotere and inhibits invasion and metastasis of breast cancer by blocking angiogenesis and the epithelial-mesenchymal transition.
Topics: Aged; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Random Allocation; Taxoids; Trypsin Inhibitors; Xenograft Model Antitumor Assays | 2013 |
Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Female; Growth Hormone-Releasing Hormone; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Sermorelin; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Chemoradiotherapy; Docetaxel; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Brain; Cell Movement; Cell Proliferation; Docetaxel; Endocytosis; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Sequence Data; Nanoparticles; Neovascularization, Pathologic; Peptides; Pericytes; Rats; Rats, Sprague-Dawley; Taxoids | 2014 |
Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cisplatin; Docetaxel; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptide Initiation Factors; Proportional Hazards Models; Protein Binding; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Taxoids; Time Factors; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Bridged-Ring Compounds; Cells, Cultured; Docetaxel; Endothelial Cells; Fluorocarbons; Integrin alphaVbeta3; Nanoparticles; Neoplasms, Experimental; Neovascularization, Pathologic; Phospholipases; Prodrugs; Rabbits; Taxoids | 2014 |
Correlation of tumor-infiltrative lymphocyte subtypes alteration with neoangiogenesis before and after neoadjuvant chemotherapy treatment in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Forkhead Transcription Factors; Humans; Immunohistochemistry; Immunophenotyping; Lymphocyte Subsets; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Stromal Cells; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids; Tumor Microenvironment | 2014 |
Cyclic-RGDfK peptide conjugated succinoyl-TPGS nanomicelles for targeted delivery of docetaxel to integrin receptor over-expressing angiogenic tumours.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Male; Micelles; Nanostructures; Neovascularization, Pathologic; Peptides, Cyclic; Polyethylene Glycols; Prostatic Neoplasms; Receptors, Cell Surface; Taxoids; Vitamin E | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Ramucirumab; Taxoids; Therapies, Investigational | 2016 |
MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Calcium-Binding Proteins; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Female; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Signaling Peptides and Proteins; MCF-7 Cells; Mice; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; Neovascularization, Physiologic; Receptor, Notch1; Taxoids; Time Factors; Xenograft Model Antitumor Assays | 2016 |
The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Contrast Media; Coordination Complexes; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Taxoids | 2016 |
Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Cycle; Cell Line, Tumor; Cell Survival; Daunorubicin; Docetaxel; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Plant Extracts; Prostatic Neoplasms; Taxoids; Tripterygium | 2016 |
Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Topics: A549 Cells; Angiogenesis Inhibitors; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent.
Topics: Animals; Avian Proteins; Breast Neoplasms; Cell Movement; Cell Proliferation; Chick Embryo; Chickens; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Neovascularization, Pathologic; Palladium; Spermine; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Body Fluids; Cell Line, Tumor; Cell Movement; Disease Progression; Docetaxel; Female; Fibroblasts; Humans; Metalloproteases; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; NIH 3T3 Cells; Oligopeptides; Ovarian Neoplasms; Peritoneum; Receptor, PAR-1; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Chemotaxis; Docetaxel; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Phenotype; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Taxoids; Thrombospondin 1; Tumor Cells, Cultured | 2009 |
A spatial model of tumor-host interaction: application of chemotherapy.
Topics: Antineoplastic Agents; Computer Simulation; Docetaxel; Endothelial Cells; Humans; Models, Immunological; Neoplasms; Neovascularization, Pathologic; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma 256, Walker; Cell Line; Cell Migration Inhibition; Cell Proliferation; Docetaxel; Endothelial Cells; Female; Humans; Neovascularization, Pathologic; Paclitaxel; Rats; Rats, Wistar; Stem Cells; Taxoids | 2009 |
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Taxoids; Thromboplastin; Treatment Outcome | 2010 |
Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ascites; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Female; Humans; Immunohistochemistry; Injections, Intraperitoneal; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2010 |
The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo.
Topics: Animals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Disintegrins; Docetaxel; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 2010 |
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Endometrial Neoplasms; Female; Gene Expression; Humans; Ki-67 Antigen; Mice; Microvessels; Molecular Targeted Therapy; Neovascularization, Pathologic; Phosphorylation; Prognosis; Receptor Protein-Tyrosine Kinases; Receptor, EphA2; Receptors, Estrogen; Receptors, Progesterone; Survival; Taxoids; Vascular Endothelial Growth Factor A | 2010 |
Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft.
Topics: Angiopoietin-2; Animals; Antineoplastic Agents; Delayed-Action Preparations; Docetaxel; Drug Carriers; Female; Fibroblast Growth Factor 2; Gene Expression; Humans; Lactic Acid; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Microspheres; Neovascularization, Pathologic; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Real-Time Polymerase Chain Reaction; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Line; Cell Movement; Cell Proliferation; Docetaxel; Endothelial Cells; Hyaluronan Receptors; Immunophilins; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Peptide Fragments; Rats; Recombinant Proteins; RNA, Small Interfering; Signal Transduction; Tacrolimus Binding Proteins; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bridged-Ring Compounds; Calcium-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Endothelial Cells; Epithelial Cells; Female; Hedgehog Proteins; Humans; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Kruppel-Like Transcription Factors; Membrane Proteins; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Nuclear Proteins; Ovarian Neoplasms; Receptors, Notch; RNA Interference; RNA, Small Interfering; Serrate-Jagged Proteins; Stromal Cells; Taxoids; Transcription Factors; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2011 |
Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cells, Cultured; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gossypol; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Neovascularization, Physiologic; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Catechin; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Tumor-targeted drug delivery using MR-contrasted docetaxel - carboxymethylcellulose nanoparticles.
Topics: Animals; Carboxymethylcellulose Sodium; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Magnetic Resonance Imaging; Male; Mice; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Staining and Labeling; Subcutaneous Tissue; Taxoids; Tissue Distribution; Treatment Outcome | 2012 |
Non-invasive quantification of tumor vascular architecture during docetaxel-chemotherapy.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Female; Humans; Mammary Neoplasms, Experimental; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Rats; Regional Blood Flow; Taxoids; Treatment Outcome; Tumor Burden; Ultrasonography | 2012 |
Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Neovascularization, Pathologic; Receptor, ErbB-2; Severity of Illness Index; Taxoids; Transforming Growth Factor beta1 | 2012 |
Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Movement; Cells, Cultured; Centrosome; Collagen; Docetaxel; Drug Combinations; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; In Vitro Techniques; Laminin; Mice; Mice, Inbred C57BL; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Proteoglycans; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays | 2002 |
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2003 |
Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model.
Topics: Adenoviridae; Angiostatins; Animals; Antineoplastic Agents, Phytogenic; Cells, Cultured; Combined Modality Therapy; Docetaxel; Drug Therapy, Combination; Endothelium, Vascular; Genetic Therapy; Genetic Vectors; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2003 |
Cancer gene therapy: lessons learned from experiences with chemotherapy.
Topics: Adenoviridae; Angiostatins; Animals; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Genetic Therapy; Humans; Male; Mice; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids | 2003 |
Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Survival; Docetaxel; Erythrocytes; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia P388; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Skin; Stilbenes; Taxoids; Transfection; Vascular Endothelial Growth Factor A; Vincristine | 2003 |
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protease Inhibitors; Pyrazines; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Blood Proteins; Cell Division; Chemistry, Pharmaceutical; Docetaxel; Drug Interactions; Endothelium, Vascular; Excipients; Glycerol; Humans; In Vitro Techniques; Male; Neovascularization, Pathologic; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Protein Binding; Rats; Rats, Sprague-Dawley; Taxoids | 2004 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A | 2004 |
Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; Cyclohexanes; Docetaxel; Drug Interactions; Humans; Male; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Tumor Cells, Cultured | 2005 |
A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice.
Topics: Animals; Anions; Antibodies, Monoclonal; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Synergism; Endothelial Cells; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Neovascularization, Pathologic; Phosphatidylserines; Phospholipids; Taxoids; Xenograft Model Antitumor Assays | 2005 |
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Cell Line; Cell Line, Tumor; Cisplatin; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Endothelial Cells; Fas Ligand Protein; fas Receptor; Flow Cytometry; Humans; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Oligopeptides; Platelet Endothelial Cell Adhesion Molecule-1; Taxoids; Thrombospondins; Xenograft Model Antitumor Assays | 2005 |
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids; Thalidomide | 2006 |
Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Cell Division; Disease Models, Animal; Docetaxel; Drug Therapy, Combination; Flavonoids; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Neovascularization, Pathologic; Piperidines; Prostatic Neoplasms; Taxoids; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.
Topics: Androgen Antagonists; Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Synergism; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Nitriles; Prostatic Neoplasms; Radionuclide Imaging; Sesquiterpenes; Taxoids; TNF Receptor-Associated Factor 1; TNF Receptor-Associated Factor 2; Tosyl Compounds; Umbilical Veins; Vascular Endothelial Growth Factor A | 2006 |
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Survival; DNA, Neoplasm; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Purines; Taxoids | 2007 |
Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Body Weight; Cell Cycle Proteins; Cell Proliferation; Docetaxel; Drug Therapy, Combination; Fluorouracil; Humans; Male; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Organ Size; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Female; Fluorodeoxyglucose F18; G2 Phase; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Serine; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Middle Aged; Neoplasms, Experimental; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Survival Analysis; Taxoids; Vascular Endothelial Growth Factor A | 2007 |
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Docetaxel; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Immunohistochemistry; Interleukin-8; Kaplan-Meier Estimate; Liposomes; Mice; Mice, Nude; Microcirculation; Middle Aged; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Ovarian Neoplasms; Phosphorylation; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Taxoids; Up-Regulation | 2008 |
[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillaries; Carcinoma, Squamous Cell; Docetaxel; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 1999 |
Biological basis for chemo-radiotherapy interactions.
Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids | 2002 |
A mouse model for the study of factors affecting angiogenesis.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Docetaxel; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Humans; Ifosfamide; Injections, Subcutaneous; Mice; Neovascularization, Pathologic; Paclitaxel; Prostheses and Implants; Surgical Sponges; Taxoids | 2002 |